 Home > Active Ingredient News > Drugs Articles > Today, Sanofi's "clopidogrel aspirin tablets" was approved in China

Today, Sanofi's "clopidogrel aspirin tablets" was approved in China

 Last Update: 2021-10-21
 Source: Internet
 Author: User

Tags

nk1 receptor antagonist

drug website

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Today, China’s National Food and Drug Administration (NMPA) announced that Sanofi’s application for the listing of the 5.
1 category of new drug "clopidogrel aspirin tablets" has been approved
.

Public information shows that this is an anti-platelet single-tablet compound (SPC) , which is suitable for preventing atherosclerotic thrombosis in adult patients with acute coronary syndrome who have taken clopidogrel and aspirin at the same time

This is an anti-platelet single-tablet compound preparation (SPC)

Screenshot source: NMPA official website

From the point of view of the mechanism of action, aspirin is an inhibitor of cyclooxygenase in the process of arachidonic acid metabolism, which can inhibit the synthesis of TXA2 .
This process is irreversible, thus inhibiting platelet metabolism, thereby changing blood rheology, and inhibiting the formation of thrombus.
Role
.

Clopidogrel is mainly an antagonist of platelet P2Y12 receptors .

Aspirin is an inhibitor of cyclooxygenase during the metabolism of arachidonic acid.

According to the "Chinese Expert Consensus on Clopidogrel/Aspirin Monolithic Compound Antiplatelet Therapy" initiated and formulated by the Cardiovascular Physicians Branch of the Chinese Medical Doctor Association in 2021, the results of multiple clinical studies show that clopidogrel/aspirin monolithic compound preparations Its antiplatelet effect is not inferior to single-agent combination therapy, and its tolerance is equivalent
.

The antiplatelet effect is not inferior to single-agent combination therapy, and the tolerability is equivalent

According to the consensus, in addition to efficacy, the special process of clopidogrel/aspirin single-tablet compound preparation can also reduce adverse reactions
.

The core of the compound preparation is 100mg aspirin; the middle is an enteric coating layer that can release aspirin in the intestines but does not dissolve in the stomach; the outer layer is an immediate release layer containing clopidogrel sulfate 75mg, which can take effect quickly

Special technology can also reduce adverse reactions.

According to Sanofi's public information, the development of a single-tablet compound preparation of clopidogrel/aspirin simplifies the treatment plan
.

This not only facilitates patient management, but is also expected to improve clinical prognosis

Reference materials:

[1] On October 11, 2021, the drug approval document pending information is released.

[2] Xu Yawei, Zhang Shuning.

[3] Li Biyan, Song Zulan, Chen Yu.
The clinical efficacy of aspirin combined with clopidogrel in the treatment of acute cerebral infarction[J].
Contemporary Medicine, 2021.
27(26): 18-20.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.